ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2017
A new role for evoked potentials in MS? Repurposing evoked potentials as biomarkers for clinical trials in MS.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed.
- Rethinking prognosis in multiple sclerosis: a multiaxial perspective.Nature reviews. Neurology · 2026Review
- Subclinical Optic Nerve Involvement in Radiologically Isolated Syndrome: Multimodal Detection and Diagnostic Impact.Annals of clinical and translational neurology · 2026Article
- Combining magnetic resonance imaging and evoked potentials enhances machine learning prediction of multiple sclerosis disability worsening.Frontiers in immunology · 2026Article
- Effect of Acute Exercise on P300 Event-Related Potential and Its Correlation With Blood Lactate Levels.Cureus · 2025Article
- Correspondence of MRI and nTMS With EDSS in Multiple Sclerosis: Longitudinal Follow-Up Study.Annals of clinical and translational neurology · 2025Observational
- Identifying Biomarkers for Remyelination and Recovery in Multiple Sclerosis: A Measure of Progress.Biomedicines · 2025Review
- Article
- Multimodal Neuroimaging and Electrophysiological Markers in Multiple Sclerosis: An Integrative Review of fMRI, EEG, and EMG Approaches : fMRI, EEG, EMG in Multiple Sclerosis.Galen medical journal · 2025Review
- Prolonged Visual Evoked Potential Latencies in Dogs Naturally Infected with Canine Distemper Virus.Viruses · 2024Article
- Evolution of retinal degeneration and prediction of disease activity in relapsing and progressive multiple sclerosis.Nature communications · 2024Article
- Expression of CD40 and CD192 in Classical Monocytes in Multiple Sclerosis Patients Assessed with Transcranial Magnetic Stimulation.Biomedicines · 2023Article
- The Importance of Optical Coherence Tomography in the Diagnosis of Atypical or Subclinical Optic Neuritis: A Case Series Study.Journal of clinical medicine · 2023Article
- Article
- First activity and interactions in thalamus and cortex using raw single-trial EEG and MEG elicited by somatosensory stimulation.Frontiers in systems neuroscience · 2023Article
- Neurophysiological and behavioural correlates of ocrelizumab therapy on manual dexterity in patients with primary progressive multiple sclerosis.Journal of neurology · 2022Article
- Relapsing MRI-negative myelitis associated with myelin-oligodendrocyte glycoprotein autoantibodies: a case report.BMC neurology · 2022Article
- Current and Future Biomarkers in Multiple Sclerosis.International journal of molecular sciences · 2022Review
- Motor evoked potentials for multiple sclerosis, a multiyear follow-up dataset.Scientific data · 2022Article
- Long-term Effect of Permanent Demyelination on Axonal Survival in Multiple Sclerosis.Neurology(R) neuroimmunology & neuroinflammation · 2022Article
- Refinement of axonal conduction and myelination in the mouse optic nerve indicate an extended period of postnatal developmental plasticity.Developmental neurobiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Evoked potentials (EP) characterize signal conduction in selected tracts of the central nervous system in a quantifiable way. Since alteration of signal conduction is the main mechanism of symptoms and signs in multiple sclerosis (MS), multimodal EP may serve as a representative measure of the functional impairment in MS. Moreover, EP have been shown to be predictive for disease course, and thus might help to select patient groups at high risk of progression for clinical trials. EP can detect deterioration, as well as improvement of impulse propagation, independently from the mechanism causing the change. Therefore, they are candidates for biomarkers with application in clinical phase-II trials. Applicability of EP in multicenter trials has been limited by different standards of registration and assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.